Shopko names new VP
GREEN BAY, Wis. Shopko announced that Dianne Parker has been appointed VP customer relationship marketing.
Parker joins Shopko from School Specialty Inc., in Greenville, Wis., where she served as VP database and direct marketing. Prior to School Specialty, Parker held the position of VP integrated marketing and Internet at Lands’ End in Dodgeville, Wis.
CPSC, Health Canada find no link between Pampers Dry Max and diaper rash
CINCINNATI The U.S. Consumer Product Safety Commission and Health Canada announced Friday that they have found no cause linking Pampers Dry Max diapers and reports of diaper rash and other skin conditions.
"We are thankful that the U.S. CPSC and Health Canada conducted their thorough reviews and have not identified any cause for concern with Pampers with Dry Max," said Jodi Allen, VP of Pampers. "Our heartfelt mission is always to care for and protect babies, and, as such, safety is, and will always be, our No. 1 priority. We hope that today’s announcement will reassure the millions of moms, dads and child caregivers who place their trust in Pampers and Dry Max every day. We thank our customers for their continued support and greatly value and appreciate the trust they place in us."
To help parents battle diaper rash, Pampers is sponsoring the distribution of comprehensive educational materials produced by the American Academy of Pediatrics that provide detailed information on the care and treatment of infant skin conditions, including diaper rash, according to Allen. The AAP materials are available as free brochures and will appear in the summer issue of AAP Healthy Children Magazine, as well as online at HealthyChildren.org and at Pampers.com.
Pfizer ends brain cancer drug development deal with Celldex
NEEDHAM, Mass. Pfizer is pulling out of a development deal for a potential brain cancer drug, saying it is not a strategic priority, according to the drug’s developer Celldex Therapeutics.
Celldex said it will regain full worldwide rights to develop and sell rindopepimut from Pfizer. The drug candidate also is called CDX-110. In May, the company reported positive results form a midstage study on the drug.
Celldex will regain rights to the drug candidate on Nov. 1.